Zhong Ouyang
Overview
Explore the profile of Zhong Ouyang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma J, Wang J, Xu T, Ouyang Q, Wang X, Wang J, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39825877
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness...
2.
Shi Y, Zhang Q, Wang J, Ouyang Z, Yi T, Mei J, et al.
Chin Med J (Engl)
. 2025 Jan;
138(4):496-498.
PMID: 39820410
No abstract available.
3.
Xie W, Hu J, Zhao Z, Lu H, Han Y, Li B, et al.
Sci Rep
. 2024 Dec;
14(1):30733.
PMID: 39730431
Platelets possess cancer-induced reprogramming properties, thereby contributing to RNA profile alterations and further cancer progression, while the former is considered a promising biosource for cancer detection. Hence, tumor-educated platelets (TEP)...
4.
Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, et al.
JAMA
. 2024 Dec;
333(8):673-681.
PMID: 39671272
Importance: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1...
5.
Zhang Y, Sun C, Yau V, Chen S, Yang Q, Chen W, et al.
Technol Cancer Res Treat
. 2023 Jun;
22:15330338231184990.
PMID: 37386809
With the improvement of diagnostic techniques, numerous uncommon metastases derived from breast cancer were reported. However, very few studies explored the clinical characteristics and prognostic patterns of these patients. A...
6.
Bi J, Wu Z, Zhang X, Zeng T, Dai W, Qiu N, et al.
Nat Commun
. 2023 Apr;
14(1):2342.
PMID: 37095176
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor outcome and lacks of approved targeted therapy. Overexpression of epidermal growth factor receptor (EGFR) is found in more...
7.
Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway and
Meng M, Yang Q, Ouyang Z, Yang Q, Wu X, Huang Y, et al.
Acta Pharm
. 2023 Jan;
73(1):75-90.
PMID: 36692465
Breast cancer is one of the most common malignant tumors in women and it is the most frequently diagnosed cancer in the world. Ampelopsin (AMP) is a purified component from...
8.
Zhang Y, Chen W, Chen S, Yang Q, Ouyang Z
Technol Cancer Res Treat
. 2022 Oct;
21:15330338221132926.
PMID: 36310472
Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Between February 2019...
9.
Li H, Li Z, He X, Zhang F, Ouyang Z, Wu G, et al.
J Card Surg
. 2022 Jul;
37(10):3060-3069.
PMID: 35842821
Background: To address intraoperative bleeding in cardiac surgery, reducing blood transfusion requirements, is mandatory to achieve effective hemostasis. Hemostatic agents may limit localized persistent bleeding. The introduction of carboxymethyl-chitosan component...
10.
Su Y, Zheng X, Ouyang Z
Iran J Public Health
. 2021 Nov;
50(9):1773-1782.
PMID: 34722372
Background: Curative operation is the practical and primary therapy for masses of breast cancers. In contrast, the correlation between the time interval from breast cancer diagnosis to curative surgery and...